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160The effect of postoperative myocardial ischemia on
long-term survival after vascular surgery
Jessica P. Simons, MD,MPH,a Donald T. Baril, MD,a Philip P. Goodney, MD,MS,b Daniel J. Bertges, MD,c
William P. Robinson, MD,a Jack L. Cronenwett, MD,b Louis M. Messina, MD,a and Andres Schanzer, MD,a
on behalf of the Vascular Study Group of New England, Worcester, Mass; Lebanon, NH; and Burlington, Vt
Introduction: The impact of a postoperative troponin elevation on long-term survival after vascular surgery is not well-
deﬁned. We hypothesize that a postoperative troponin elevation is associated with signiﬁcantly reduced long-term
survival.
Methods: The Vascular Study Group of New England registry identiﬁed all patients who underwent carotid revascu-
larization, open abdominal aortic aneurysm repair (AAA), endovascular AAA repair, or infrainguinal lower extremity
bypass (2003-2011). The association of postoperative troponin elevation and myocardial infarction (MI) with 5-year
survival was evaluated. Multivariable models identiﬁed predictors of survival and of postoperative myocardial
ischemia.
Results: In the entire cohort (n[ 16,363), the incidence of postoperative troponin elevation was 1.3% (n[ 211) and for
MI was 1.6% (n [ 264). Incidences differed across procedures (P < .0001) with the highest incidences after open AAA:
troponin elevation, 3.9% (n[ 74); MI, 5.1% (n[ 96). On Kaplan-Meier analysis, any postoperative myocardial ischemia
predicted reduced survival over 5 years postoperatively: no ischemia, 73% (standard error [SE], 0.5%); troponin elevation,
54% (SE, 4%); MI, 33% (SE, 4%) (P < .0001). This pattern was observed for each procedure subgroup analysis
(P < .0001). Troponin elevation (hazard ratio, 1.45; 95% conﬁdence interval, 1.1-2.0; P [ .02) and MI (hazard ratio,
2.9; 95% conﬁdence interval, 2.3-3.8; P < .0001) were independent predictors of reduced survival at 5 years.
Conclusions: Postoperative troponin elevation and MI predict a 26% or a 55% relatively lower survival in the 5 years
following a vascular surgical procedure, respectively, compared with patients who do not experience myocardial ischemia.
This highlights the need to better characterize factors leading to postoperative myocardial ischemia. Postoperative
troponin elevation, either alone, or in combination with an MI, may be a useful marker for identifying high-risk patients
who might beneﬁt from more aggressive optimization in hopes of reducing adverse long-term outcomes. (J Vasc Surg
2013;58:1600-8.)Cardiovascular death remains a major cause of late
mortality following vascular surgical procedures.1-4 The
prevalence of coronary artery disease (CAD) in this patient
population has been well-documented, beginning with
a large review from the Cleveland Clinic nearly 30 years
ago5 demonstrating that 92% of patients undergoing major
vascular surgical procedures have signiﬁcant CAD when
screening cardiac catheterization is performed. Similarly,
postoperative cardiac events remain a signiﬁcant source of
morbidity and mortality associated with vascular operations.
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0(MI) negatively impacts both short- and long-term
survival.4,6-9 In a recent series, utilizing Vascular Study
Group of New England (VSGNE) data, postoperative MI
was correlated with worse survival following carotid revascu-
larization.10 Troponin elevations have also been shown to
correlate with negative outcomes for a wide range of diag-
noses, from acute coronary syndromes,11,12 to critically ill
medical patients,13 to all types of noncardiac surgical
procedures,14 and to vascular surgical procedures in partic-
ular.6,15,16 Because it does not, in isolation, constitute an
MI, many clinicians, both surgeons and consulting nonsur-
geons alike, express less concern for troponin elevations;
however, the long-term survival implications of these events
remain uncertain. Troponin is a regulatory protein associ-
ated with contraction of myocardial muscle cells; serum
elevations of troponin are believed to correlate withmyocyte
injury from myocardial ischemia.17 The universal deﬁnition
of MI classiﬁes myocardial ischemia into ﬁve types based on
the associated pathophysiology; themajority of patients who
sustain myocardial ischemia following noncardiac surgery
are believed to have type 2 ischemia, which relates to an
imbalance in supply and demand of myocardial oxygen,
which can result from many perioperative factors including
anemia or hypotension, with or without underlying cardiac
disease.18We sought to determine the association of postop-
erative troponin elevationwith long-term survival in patients
undergoing vascular surgical procedures.
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Study design. Prospectively collected data from the
VSGNE database was retrospectively reviewed to identify
all patients who underwent carotid angioplasty and stent
placement, carotid endarterectomy (CEA), open infrarenal
abdominal aortic aneurysm (AAA) repair, endovascular
AAA repair, and infrainguinal lower extremity bypass
between January 1, 2003 and December 31, 2011. The
VSGNE is a regional cooperative quality improvement
initiative, developed in 2002, to prospectively evaluate
outcomes in patients undergoing vascular surgical proce-
dures. It is comprised of 140 physicians from 25 academic
and community medical centers across New England.
Details of this registry have been published previously19
and are available online (www.vsgne.org). Data are
physician-reported at the time of operation and include
preoperative, intraoperative, and in-hospital postoperative
details. Follow-up data are entered at approximately 1 year
postoperatively. All information is sent to a central data
repository where it is aggregated and audited. Research
analysts are blinded to patient, surgeon, and hospital
identity.
Primary end point and exposure variable. The
primary end point was long-term survival. Survival was
determined by matching patients in the registry with the
Social Security Death Index. An adjusted analysis of
survival over the ﬁrst 5 years postoperatively was also
constructed, using the mean of all nonexposure variables.
An additional exploratory analysis of survival was done that
excluded patients who died within 30 days of operation in
order to test whether an effect is driven by fatal MI only.
The primary exposure variable was postoperative
myocardial ischemia. Postoperative myocardial ischemia
was categorized using variables that are collected postoper-
atively in the VSGNE dataset in the following manner: (1)
a troponin elevation beyond the normal upper limit, as
deﬁned by the testing laboratory, without electrocardio-
graphic (ECG) changes or (2) clinical symptoms (severe
chest pain and/or radiation to the left arm or jaw) and/or
ECG changes consistent with MI, as deﬁned at each partici-
pating institution. The precise nature of the ECG changes
(ST elevations, Q waves, etc) was not speciﬁed. The primary
exposure variable, “postoperative ischemia,” is nominal
with three possible levels: no ischemia, troponin elevation
only, or MI. The hierarchy of the variable ensures that
patients were not dually classiﬁed as both “troponin only”
and “clinical/ECG MI”; the “clinical/ECG MI” super-
sedes the other designation. Patients were not routinely
screened for troponin elevations or postoperative ECG
changes; they were obtained at the discretion of the
provider postoperatively, based on clinical suspicion or
risk factor prevalence. Therefore, it is not possible to
know the total number of patients for whom troponin
assays were sent, but resulted within normal limits. In addi-
tion, a literal interpretation of the second part leaves open
the possibility that patients who experienced clinical symp-
toms alone would be categorized as having sustained anMI.Since most practitioners would likely not consider this sufﬁ-
cient evidence to make that diagnosis, we have assumed that
there would be very few instances of this misclassiﬁcation
when reporting outcomes also. We instead suspect that
most often, this variable is understood to mean clinical
symptoms in addition to troponin elevation, since the other
levels of this nominal variable are “no MI,” or troponin
elevation only. Troponin levels were categorized as elevated
or normal but not quantiﬁed as a continuous variable.
Covariates examined. Patient information for >100
clinical and demographic variables (available at www.vsgne.
org) was collected. Demographic information included
age at the timeof the procedure, gender, and race.Comorbid-
ities examined included CAD (history of MI without current
symptoms, stable angina, or unstable angina or MI within
the past 6 months), chronic obstructive pulmonary dis-
ease (COPD; medication-dependent or home oxygen-
dependent), congestive heart failure (CHF; by history),
diabetes mellitus (DM; insulin-dependent and/or controlled
by oral medication or diet), hypertension (HTN; history of
hypertension or blood pressure $140/90 mm Hg on the
preoperative evaluation), and history of tobacco use
(never, <1 year prior, or current). Renal disease was catego-
rized in three strata: normal (serum creatinine#1.8mg/dL),
renal insufﬁciency (serum creatinine >1.8 mg/dL), and
dialysis-dependent. Results of preoperative stress testing was
deﬁned as not performed, negative for ischemia, or positive
for ischemia, MI, or both. History of previous coronary
revascularization included both coronary artery bypass graft
or percutaneous coronary intervention. While statin use is
recorded in the database, there is no information on speciﬁc
lipid levels; the use of a statin was not considered a proxy for
hyperlipidemia.
Medication use was recorded, including beta-blockers,
antiplatelet agents (aspirin, clopidogrel, or both), and sta-
tins. Information was available both on the use of these
medications preoperatively, as well as at the time of
discharge. Data regarding preoperative medication use
were included as covariates on multivariable modeling of
postoperative myocardial ischemia, while medication use
at the time of discharge was used in multivariable modeling
of long-term survival; this was based on our clinical judg-
ment of the relevance of the timing of medication use rela-
tive to the end point of interest.
Subgroup analyses were performed by procedure type,
which included carotid revascularization, open AAA repair,
endovascular AAA repair, and lower extremity bypass.
Carotid revascularization was deﬁned as either CEA or
carotid stenting (CAS); the two procedures were grouped
together because exploratory analyses revealed that the
two groups were not statistically different and that the
primary outcome event incidences were very low (<1%)
in the carotid stenting group. Lower extremity bypass
was limited to infrainguinal bypass. Elective, urgent, and
emergent cases were included.
Statistical analysis. Descriptive statistics were used to
assess the incidence of postoperative myocardial ischemia.
Table I. Demographics for patients in the VSGNE cohort (2003-2011), stratiﬁed according to postoperative isolated
troponin elevation, MI, or no ischemia
Covariate
Total
(n ¼ 16,363)
No ischemia
(n ¼ 15,888)
Troponin elevation
(n ¼ 211)
MI
(n ¼ 264)
P
value
Demographics
Age, years 69.8 6 10 69.7 6 10 73.1 6 8.7 72.8 6 9.2 <.0001
Gender (male) 10908 (66.7) 10593 (66.7) 148 (70.1) 167 (63.3) .28
Preoperative factors
Smoking status .55
Never 2797 (17.1) 2726 (17.2) 33 (15.8) 38 (14.3)
Former/current 13527 (82.9) 13134 (82.8) 176 (84.2) 217 (85.1)
COPD <.0001
None/not treated 13764 (84.2) 13409 (84.4) 152 (72.4) 203 (77.8)
Medications 2190 (13.4) 2098 (13.2) 46 (21.9) 46 (17.6)
Home oxygen 396 (2.4) 372 (2.3) 12 (5.7) 12 (4.6)
CAD <.0001
None 10850 (66.4) 10634 (67) 94 (44.8) 122 (47.5)
History of MI, asymptomatic 3415 (20.9) 3276 (20.6) 7 (34.3) 67 (26.1)
Stable angina 1794 (11) 1697 (10.7) 42 (20) 55 (21.4)
Unstable angina or MI within 6 months 278 (1.7) 277 (1.7) 4 (1.8) 13 (5.1)
History of coronary revascularization 5136 (31.4) 4973 (31.3) 74 (35.1) 89 (34.5) .29
Stress testing .01
Not performed 9783 (60.1) 9510 (60.2) 120 (57.1) 153 (58.4)
Normal 4550 (28) 4437 (28.1) 53 (25.2) 60 (22.9)
Ischemia/MI/both 1944 (11.9) 1858 (11.8) 37 (17.6) 49 (18.7)
CHF 1716 (10.5) 1598 (10.1) 57 (27.1) 61 (23.6) <.0001
HTN 14091 (86.2) 13663 (86) 188 (89.1) 240 (92.3) .01
DM 5243 (32.1) 5044 (31.8) 89 (42.4) 110 (42.3) <.0001
Renal function <.0001
Cr #1.8 mg/dL 14622 (92.5) 14244 (91.8) 160 (78.1) 218 (86.9)
Cr >1.8 mg/dL 1037 (6.5) 972 (6.3) 38 (18.5) 27 (10.8)
Dialysis-dependent 318 (2) 305 (2) 7 (3.4) 6 (2.4)
Preoperative medications
Antiplatelet agent 13291 (81.3) 12929 (81.4) 157 (74.8) 205 (80.1) .04
Beta blocker 12725 (77.9) 12337 (77.7) 170 (81) 218 (83.5) .05
Statin 11507 (70.4) 11188 (70.5) 141 (67.1) 178 (69.3) .25
Postoperative medications
Antiplatelet agent 13491 (87.9) 13177 (87.9) 147 (85) 167 (88.8) .46
Beta blocker 9592 (76.2) 9336 (76) 122 (80.8) 134 (85.4) .01
Statin 9841 (78.1) 9603 (78.1) 114 (75.5) 124 (79) .72
Procedure type <.0001
Carotid revascularization 8317 (50.8) 8229 (51.8) 38 (18) 50 (18.9)
AAA (open) 1883 (11.5) 1713 (10.8) 74 (35.1) 96 (36.4)
AAA (endovascular) 2172 (13.3) 2118 (13.3) 27 (12.8) 27 (10.2)
Lower extremity bypass 3991 (24.4) 3828 (24.1) 72 (34.1) 91 (34.5)
AAA, Abdominal aortic aneurysm; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus; HTN, hypertension; MI, myocardial infarction; VSGNE, Vascular Study Group of New England.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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continuous variable, age, and c2 analysis for all other vari-
ables, which were categorical variables; this included all
demographic information (other than age), comorbid
conditions, procedure type, and medication use. Survival
analyses were performed according to the Kaplan-Meier
method, with intergroup comparisons made using log-
rank testing. Analyses were performed on the entire
cohort, with additional subgroup analyses based on
procedure type.
Cox proportional hazards modeling was used to deter-
mine the magnitude of effect of postoperative myocardial
ischemia on survival. An interaction term was tested in
the model to assess for interaction between procedure
type and postoperative ischemia. Multivariable logisticregression was used to assess independent predictors of
any postoperative myocardial ischemia (both isolated
troponin elevation and MI). Clinically relevant covariates
were chosen a priori to ensure face validity of the multivari-
able models. Signiﬁcance was accepted at the P < .05 level.
All analyses were conducted using SAS version 9.2 software
(SAS Institute, Cary, NC).
RESULTS
Cohort characteristics. Between January 2003 and
December 2011, a total of 16,421 patients underwent
vascular surgical procedures recorded in the VSGNE data-
base (Table I). Fifty-eight patients were excluded because
the exposure variable, postoperative myocardial ischemia,
was missing. The majority were men (n ¼ 10,908; 67%),
Table II. Event rates stratiﬁed by procedure type
Procedure type
No ischemia,
No. (%)
Troponin
elevation,
No. (%)
MI,
No. (%)
Total cohort 15,888 (97.1) 211 (1.3) 264 (1.6)
Carotid revascularization 8229 (98.9) 38 (0.5) 50 (0.6)
AAA (open) 1713 (91) 74 (3.9) 96 (5.1)
AAA (endovascular) 2118 (97.5) 27 (1.2) 27 (1.2)
Lower extremity bypass 3828 (95.9) 72 (1.8) 91 (2.3)
AAA, Abdominal aortic aneurysm; MI, myocardial infarction.
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revascularization comprised the majority of the cohort
(n ¼ 8317; 51%), with 7836 (94%) CEA and 481 (6%)
CAS procedures. There were 3991 lower extremity
bypasses (24%), 1883 open AAAs (12%), and 2172 endo-
vascular AAA (13%) procedures.
Overall, preoperative use of all three classes of cardio-
protective medications was high, with 70% of patients on
statins, 78% of patients on beta blockers, and 81% of
patients on antiplatelet agents. Patients who suffered
both types of postoperative myocardial ischemia were less
likely to be on a beta blocker (P ¼ .04) but were more
likely to be on an antiplatelet agent (P ¼ .04). Patients
with a history of CAD were more likely to experience post-
operative myocardial ischemia (P < .0001). Patients with
positive preoperative stress testing were also more likely
to experience postoperative myocardial ischemia
(P ¼ .01). Postoperative myocardial ischemia was associ-
ated with a history of CHF (P < .0001), history of
COPD (P < .0001), DM (P < .0001), HTN (P ¼ .01),
and renal insufﬁciency (P < .0001) on univariate analysis.
Postoperative events and long-term outcomes.
Postoperative myocardial ischemia occurred in 475 patients
(3%), with MI slightly more common (n ¼ 264; 2%) than
troponin elevation (n ¼ 211; 1%; Table II). On univariate
analysis, incidences of myocardial ischemia were signiﬁcantly
different between procedure types (P < .0001), with the
highest incidence after openAAA repair (troponin elevation,
n ¼ 74; 4% and MI, n ¼ 96; 5%). Postoperative myocardial
ischemia was least common after carotid revascularization,
with 38 patients experiencing troponin elevation (0.5%) and
50 patients experiencing MI (0.6%).
Kaplan-Meier analysis revealed a signiﬁcant difference
in survival over the ﬁrst 5 years postoperatively when the
cohort was stratiﬁed according to the speciﬁc type of post-
operative myocardial ischemia (Fig 1). Among those
without myocardial ischemia, survival over the ﬁrst 5 years
postoperatively was 73% (standard error [SE], 0.5%),
whereas among those with a postoperative troponin eleva-
tion or MI, survival was 54% (SE, 4%) and 33% (SE, 4%),
respectively (log-rank, P < .0001).
Adjusted Kaplan-Meier analysis, using the mean values
for nonexposure variables, demonstrated a signiﬁcant differ-
ence in survival over the ﬁrst 5 years postoperatively (Fig 2).
Among those withoutmyocardial ischemia, survival over the
ﬁrst 5 years postoperatively was 78% (SE, 0.7%), whereas
among those with a postoperative troponin elevation or
MI, survival was 48% (SE, 4%) and 35% (SE, 4%), respec-
tively (log-rank, P < .0001).
An exploratory analysis that excluded patients who died
in the perioperative period continued to demonstrate
a signiﬁcant difference in survival over the ﬁrst 5 years post-
operatively, although the point estimates were different.
Among those without myocardial ischemia, survival over
the ﬁrst 5 years postoperatively was 74% (SE, 0.5%),
whereas among those with a postoperative troponin eleva-
tion or MI, survival was 61% (SE, 5%) and 46% (SE, 5%),
respectively (log-rank, P < .0001).Subgroup analysis, using the entire cohort, by proce-
dure type demonstrated a similar trend for all procedures
(log-rank, P < .0001 for all; Fig 3).
Independent predictors of long-term survival. On
multivariable analysis, postoperative MI was a signiﬁcant
independent predictor of death over the ﬁrst 5 years of
follow-up postoperatively (hazard ratio [HR], 2.9; 95%
conﬁdence interval [CI], 2.3-3.8; P < .0001) compared
with no myocardial ischemia (Table III). Similarly, a post-
operative troponin elevation was also a signiﬁcant inde-
pendent predictor of death over the ﬁrst 5 years
postoperatively (HR, 1.5; 95% CI, 1.1-2.0; P ¼ .01)
compared with no myocardial ischemia. Compared with
carotid revascularization as the reference group, patients
undergoing lower extremity bypass had signiﬁcantly lower
5-year survival (HR, 2.0; 95% CI, 1.8-2.2; P < .0001),
while patients undergoing endovascular AAA (P ¼ .26)
and open AAA (P ¼ .14) did not. No signiﬁcant interaction
was found between procedure type and postoperative
ischemia (P ¼ .0952). Increasing age demonstrated an
inversely proportional relationship, with decreased survival
associated with each incremental increase in age strata
(compared with age <60 years; age 60-69 years, HR, 1.4;
95% CI, 1.1-1.6; P ¼ .002; age 70-79 years, HR, 2.1; 95%
CI, 1.7-2.5; P < .0001; age >80 years, HR, 4.3; 95% CI,
3.6-5.2; P < .0001).
Certain medical comorbidities were independently
associated with decreased survival over the ﬁrst 5 years
postoperatively: history of CAD (HR, 1.4; 95% CI,
1.2-1.5; P < .0001), COPD requiring medications
(HR, 1.4; 95% CI, 1.2-1.6; P < .0001), home oxygen use
(HR, 2.8; 95% CI, 2.3-3.4; P < .0001), history of DM
(HR, 1.2; 95% CI, 1.1-1.3; P ¼ .001), CHF (HR, 1.5;
95% CI, 1.3-1.7; P < .0001), renal insufﬁciency
(Cr >1.78 mg/dL, HR, 1.9; 95% CI, 1.6-2.2; P < .0001,
and dialysis dependence, HR, 4.4; 95% CI, 3.6-5.4; P <
.0001). Antiplatelet therapy at the time of discharge was
independently associated with a survival beneﬁt over the ﬁrst
5 years postoperatively (HR, 0.7; 95% CI, 0.6-0.8; P <
.0001), as was statin use (HR, 0.7; 95% CI, 0.6-0.8; P <
.0001). Beta blocker use on discharge did not confer a signif-
icant survival beneﬁt over the ﬁrst 5 years postoperatively.
Predictors of postoperative myocardial ischemia.
On logistic regression, CEA had lower odds of postopera-
tive myocardial ischemia than all other procedure types
Fig 1. Univariate Kaplan-Meier (K-M) analysis of 5-year survival among the total cohort, stratiﬁed by postoperative
myocardial ischemia; log-rank, P < .0001.
Fig 2. Kaplan-Meier analysis of 5-year survival among the total
cohort, stratiﬁed by postoperative myocardial ischemia and adjusted
for the mean values of all nonexposure variables; log-rank,
P < .0001. EKG, Electrocardiograph;MI, myocardial infarction.
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occurrence of myocardial ischemia (odds ratio [OR], 9.6;
95% CI, 7.2-12.9; P < .0001), followed by lower extremity
bypass (OR, 3.6; 95% CI, 2.7-4.8; P < .0001). History of
CAD was independently associated with postoperative
myocardial ischemia, with an increasing exposure-response
relationship (compared with no history of CAD, history of
MI but no symptoms, OR, 1.8; 95% CI, 1.4-2.3; P <
.0001; stable angina, OR, 2.5; 95% CI, 1.9-3.4; P < .0001;
unstable MI or angina within 6 months, OR, 2.6; 95% CI,
1.5-4.7; P ¼ .001). No class of cardioprotectivemedications, used preoperatively, had a signiﬁcant effect on
postoperative myocardial ischemia.DISCUSSION
This study demonstrates that, in patients undergoing
vascular surgical procedures, any postoperative myocardial
ischemia, whether a postoperative troponin elevation or
a postoperative MI, is associated with lower survival over
the ﬁrst 5 years postoperatively. While the magnitude of
effect of a troponin elevation (HR, 1.5) is smaller than
that of MI (HR, 2.9), the association with reduced
5-year survival is substantial. The exclusion of patients
who did not survive the perioperative period, a surrogate
for those with fatal cardiac events, did not impact this
trend. Also, adjustment of the Kaplan-Meier curves for
confounders changed the point estimates (by less than
10% in each exposure level), but not the overall trend, or
signiﬁcance testing. Other predictors of reduced long-
term survival identiﬁed in this population included
advanced age, COPD, CAD, CHF, DM, impaired renal
function, and a lower extremity bypass procedure.
Conversely, the use of antiplatelet agents and statins at
the time of discharge demonstrated a protective effect.
Previous studies have shown that, compared with
age-matched controls, patients undergoing major vascular
operations have decreased long-term survival.2 Cardiac
death has been shown to account for a substantial portion
of long-term mortality4 following major vascular proce-
dures. Similarly, postoperative cardiac complications have
been identiﬁed as predictors of death in both the short
and long term.6,8,20,21 This extends the ﬁndings previously
reported utilizing patients in the VSGNE who underwent
carotid revascularization, a subset of the present study’s
Fig 3. Univariate Kaplan-Meier (K-M) curves of survival at 5 years, stratiﬁed according to postoperative myocardial
ischemia, among (A) carotid revascularization; P < .0001, (B) open abdominal aortic aneurysm (AAA) repair;
P < .0001, (C) endovascular AAA repair; P < .0001, and (D) lower extremity bypass; P < .0001.
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were associated with worse 1-year and 5-year survival.10
Our ﬁndings corroborate the importance of cardiac
morbidity on survival; patients who experienced a postoper-
ative MI had a substantially lower survival over the ﬁrst
5 years postoperatively (33%; SE, 4%) than patients who
did not experience postoperative ischemia (73%; SE, .5%).
The speciﬁc inﬂuence of a postoperative troponin
elevation on short-term outcomes has been investi-
gated4,7,8,15 in previous work, but the association with
worse long-term outcomes, speciﬁcally in patients under-
going major vascular operations, has not been examined.
A recent meta-analysis demonstrated a strong association
between postoperative troponin elevation and short-term
mortality after vascular procedures.22 While not the
primary focus of the present investigation, Kaplan-Meier
analysis of survival at 1 year in our cohort conﬁrmed this
ﬁnding, with a signiﬁcant difference between the curves
(log-rank, P < .0001); for those with no ischemia, survival
at 1 year was 93% (SE, 0.2%); for toponin elevation, 76%
(SE, 3%); and for MI, 58% (SE, 3%). Our ﬁndings are
therefore in accordance with these other studies of early
survival, but extend the current body of literature by
demonstrating that the negative impact of a postoperative
troponin elevation on survival persists out to 5 years.Utilizing one of the largest cooperative data registries
of vascular surgical patients, we were able to elucidate the
signiﬁcance of a postoperative troponin elevation beyond
the previously established immediate postoperative period.
In addition, our results include several major procedure
types, and therefore represent a more diverse patient pop-
ulation than previous studies analyzing a single procedure
type.2-4 This, in combination with the varied population
obtained from both academic and community practices
throughout New England, enhances the generalizability
of these ﬁndings.
Limitations of this study include the potential for bias
based on a lack of protocol for obtaining postoperative
troponin levels on every patient. It may be that troponins
were checked in the absence of clinical symptoms only in
those patients considered at highest risk for cardiac compli-
cations. Attempts to mitigate this potential bias included
controlling for several comorbidities with the use of Cox
proportional hazards modeling, but confounding due to
unmeasured factors may persist. In addition, the incidence
of postoperative myocardial ischemia was somewhat lower
than that reported in several other large series of vascular
surgical patients. This may relate to the heterogeneous
population, with 50% of the cohort having undergone
carotid revascularization, a relatively low-risk procedure
Table III. Cox proportional hazards modeling of the
effect of postoperative myocardial ischemia on survival
Covariate HR (95% CI) P value
Postoperative myocardial ischemia
No ischemia Referent
Troponin elevation 1.45 (1.08-1.95) .01
MI 2.93 (2.26-3.8) <.0001
Demographics
Age <60 years Referent
Age 60-69 years 1.35 (1.11-1.63) .002
Age 70-79 years 2.09 (1.75-2.51) <.0001
Age $80 years 4.32 (3.59-5.2) <.0001
Female gender 1.02 (0.92-1.13) .77
Preoperative factors
Smoking status
Never Referent
Former/current 1.14 (1.0-1.3) .05
COPD
None/not treated Referent
Medications 1.38 (1.21-1.57) <.0001
Home oxygen 2.78 (2.29-3.38) <.0001
CAD 1.35 (1.2-1.51) <.0001
History of coronary
revascularization
1.0 (0.89-1.12) .97
CHF 1.48 (1.3-1.7) <.0001
HTN 0.98 (0.85-1.14) .82
DM 1.2 (1.08-1.33) .001
Renal function
Creatinine #1.8 mg/dL Referent
Creatinine >1.8 mg/dL 1.89 (1.63-2.19) <.0001
Dialysis-dependent 4.38 (3.56-5.39) <.0001
Medications at discharge
Antiplatelet agent 0.67 (0.56-0.76) <.0001
Beta blocker 0.93 (0.82-1.05) .22
Statin 0.69 (0.62-0.76) <.0001
Procedure
Carotid revascularization Referent
AAA (open) 1.14 (0.96-1.35) .14
AAA (endovascular) 1.09 (0.94-1.27) .26
Lower extremity bypass 1.98 (1.76-2.21) <.0001
AAA, Abdominal aortic aneurysm; CAD, coronary artery disease; CHF,
congestive heart failure; CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; HTN, hypertension; HR, hazard
ratio; MI, myocardial infarction.
Table IV. Logistic regression analysis of predictors of
any type of postoperative myocardial ischemia
Covariate OR (95% CI) P value
Demographics
Age <60 years Referent
Age 60-69 years 1.53 (1.04-2.24) .03
Age 70-79 years 1.87 (1.29-2.7) .0009
Age $80 years 2.39 (1.61-3.55) <.0001
Gender (female) 1.27 (1.03-1.57) .03
Preoperative factors
Smoking status
Never Referent
Former/current 1.07 (0.81-1.42) .63
COPD
None/not treated Referent
Medications 1.25 (0.97-1.61) .09
Home oxygen 1.59 (1.0-2.52) .05
CAD
None Referent
History of MI, asymptomatic 1.77 (1.37-2.27) <.0001
Stable angina 2.53 (1.9-3.37) <.0001
Unstable angina or MI within
6 months
2.65 (1.48-4.75) .001
History of coronary
revascularization
0.70 (0.56-0.89) .003
CHF 1.9 (1.48-2.45) <.0001
HTN 1.46 (1.02-2.08) .04
DM 1.63 (1.31-2.03) <.0001
Renal function
Creatinine #1.8 mg/dL Referent
Creatinine >1.8 mg/dL 1.58 (1.18-2.13) .002
Dialysis-dependent 0.77 (0.43-1.4) .39
Preoperative medications
Antiplatelet agent 1.18 (0.91-1.51) .21
Beta blocker 1.03 (0.79-1.35) .82
Statin 1.12 (0.89-1.4) .34
Procedure
Carotid revascularization Referent
AAA (open) 9.62 (7.21-12.85) <.0001
AAA (endovascular) 2.17 (1.51-3.13) <.0001
Lower extremity bypass 3.61 (2.73-4.76) <.0001
AAA, Abdominal aortic aneurysm; CAD, coronary artery disease; CHF,
congestive heart failure; CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; HTN, hypertension; MI,
myocardial infarction; OR, odds ratio.
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inherent to the structure of the VSGNE dataset is the deﬁ-
nition of MI as either “clinical symptoms consistent with
MI” or “ECG changes consistent with MI” without refer-
ence to troponin level. According to the American Heart
Association’s (AHA) universal deﬁnition of MI,18 at least
one troponin value above the 99th percentile is required
in addition to either of the two aforementioned criteria.
This data collection method makes it impossible to classify
patients in the VSGNE dataset according to the AHA
universal deﬁnition. Nonetheless, in aggregate, these limi-
tations would tend to overestimate the incidence of
myocardial ischemia and underestimate the effect of a post-
operative myocardial ischemia on 5-year survival.
We have shown in a contemporary diverse cohort of
more than 16,000 patients undergoing vascular surgical
procedures that survival over the ﬁrst 5 years postopera-
tively is reduced in patients experiencing a postoperativemyocardial ischemic event, including an isolated troponin
elevation. Moreover, we have established the relative
magnitude of effect on long-term survival associated with
an isolated postoperative troponin elevation (HR, 1.5)
compared with a postoperative MI (HR, 2.9). While
previous investigations have shown that postoperative
troponin elevations correlate with worse short-term
outcomes,23 this is the ﬁrst study to determine its associa-
tion with reduced long-term survival.
An important question that remains unanswered
pertains to the nature of the relationship between postop-
erative troponin elevations and reduced survival: is this
a cause-and-effect relationship, with myocardial damage
leading to worse survival, or a correlation that identiﬁes
a subset of patients at higher risk for decreased survival?
If the former is true, then efforts should focus on pre-
operative cardiac risk optimization and prevention of
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optimization are not entirely straightforward. The use of
antiplatelet agents and statins in patients undergoing
vascular procedures is recommended in consensus state-
ments.24 However, studies on the use of beta blockers in
the perioperative period have proved difﬁcult to interpret,
with one of the largest trials showing a reduction in the
incidence of postoperative MI but also an increase in the
incidence of postoperative stroke and death.25 Within our
dataset, no class of medications, used perioperatively,
demonstrated a signiﬁcant reduction in postoperative
myocardial ischemia. However, use of both statins and
antiplatelet agents at the time of discharge showed a survival
beneﬁt of 30%. While adherence to evidence-based thera-
pies such as these will likely never reach 100%, some studies
have suggested signiﬁcant room for improvement.26
Within our dataset, utilization of these medications was
generally greater than 70%, and increased utilization was
seen postoperatively compared with preoperatively. This
relative decrease in preoperative cardioprotective medica-
tion usage may represent a potential opportunity for
system-based quality improvement initiatives.
To date, there are no established guidelines for
measuring troponin levels after vascular surgical procedures.
While routine serial measurements of cardiac enzymes, for
all patients regardless of clinical factors, have certainly
been employed in the past, current standard of care does
not call for this, nor is it widely practiced. The results of
this study do not allow for determination of the value of
routine screening of cardiac biomarkers. However, this
investigation highlights that postoperative troponin eleva-
tion, either alone, or in combination with clinical or ECG
evidence of ischemia, may be useful in identifying a high-
risk subset of patients that potentially warrants more aggres-
sive postprocedural treatment to avoid adverse long-term
outcomes. It remains unclear whether these events cause
this worsened survival, or instead, simply identify a subset
of patients at higher risk for death in the long term.
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Submitted Mar 11, 2013; accepted Jun 5, 2013.DISCUSSIONDr Julie Ann Freischlag (Baltimore, Md). Could you deﬁne
how a myocardial infarction was determined, and what you
required in order to make that diagnosis?
Dr Jessica P. Simons. The way that the data capture postop-
erative myocardial ischemia are categorized as none, troponin
elevation only, or clinical or EKG evidence of MI.
Myocardial infarction is deﬁned at the discretion of the
surgeon, ultimately, when they ﬁll out the data sheets, but it
includes either clinical evidence of myocardial infarction, such as
chest pain or EKG changes consistent with an MI.
Dr Jon Matsumura (Madison, Wisc). What are the criteria to
screen a patient with a troponin? Were you only testing patients
who had symptoms, or was it all the patients in the database had
a routine troponin? With a prophylactic operation for aneurysm
repair or asymptomatic carotid, predicting the long-term survival
is helpful for the patient decision making.
Dr Simons. I think that’s a really excellent point, and that it
would be really helpful to know what the indication was. We don’t
have that data available to us, why a patient would have had tropo-
nins checked postoperatively. It’s not a routine part of the manage-
ment of all patients in the VSGNE, but rather, it’s at the discretion
of the surgeon.
Dr Michael Conte (San Francisco, Calif). I think that your
slide where you contrasted the implications about causality versus
association is really the most important point, because I think,
again, this information may be misinterpreted in light of the types
of conversations that surround it; for example, the CREST end
point.
And, unfortunately, your conclusion slide actually erred back
in the wrong direction by suggesting causality, the way I read it,
when you said that these postoperative events were themselves
directly related to later mortality. I think if you took 1000 cardio-
vascular patients in the clinic and gave them all a stress test, it
would be no shock to ﬁnd out that the ones that failed the stress
test would not have quite as good long-term survival as those
that passed the stress test. But, the stress test doesn’t cause the
death. That is entirely analogous to the issue with the majority
of postoperative MIs.
I think that this becomes a critical issue with interpretation of
the ﬁndings, while I concur with the importance of working to
prevent these events. My major question to you is: did you look
at whether or not all of the patients were treated according to
guidelines with cardioprotective medications? Because I think
that really is the bottom line for perioperative management. It’s
not the procedure that’s causing the late mortality, it’s really
whether or not they are getting appropriate medical care before,
during, and after.
Dr Simons. We did take a look to some extent at that,
although I think that that question is being addressed a little bitmore thoroughly with another VSGNE study. But, in brief, we
did ﬁnd that the use of statin and antiplatelet agents at the time
of discharge was protective against death in our Cox proportional
hazard model, suggesting exactly as you’re saying, that if patients
are treated medically more appropriately, then perhaps that would
be what impacts survival over the long term.
Dr John Chang (Roslyn, NY). What would be your sugges-
tions in terms of optimization preoperatively? Do you think that
everybody who has a positive stress test should go through cardiac
catheterization or revascularization?
Dr Simons. Well, I think we probably need to lean on our
cardiology colleagues a little bit more in order to ﬁgure out exactly
what the right things would be to better preoptimize patients
preoperatively and medically manage them postoperatively as
well. Certainly the data suggest a beneﬁt to medications such as
statins and antiplatelet agents for improving survival. But, beyond
that, who needs a stress test and who needs preoperative cardiac
catheterization is a question I would work with our cardiology
colleagues to better answer.
Dr Matthew Eagleton (Cleveland, Ohio). When you’re look-
ing at cause of death at 5 years, do you have any categorization as
to cause of death, such as cardiovascular death versus cancer death?
Dr Simons. We don’t have that data available to us in this
data set.
Dr Cheong Lee (Milwaukee, Wisc). Elevation in troponin can
be also related to impairment in renal function, so do you think
this is actually a reﬂection of renal impairment that you’re seeing
the elevations in troponin being related with mortality?
Dr Simons. I think it’s a little hard to know for sure. I know
that looking through our data, the percentage of patients who have
signiﬁcant renal diseaseewhich is deﬁned by a creatinine greater
than 1.8eis very small, so I suspect that that inﬂuence would be
very minor. But, that is a reasonable point.
The other confounding issue is whether troponins were
checked disproportionally among those patients with renal failure,
which would bias the data. So, I can’t really answer that question
speciﬁcally.
Dr Amy Reed (Hershey, Pa). I’m assuming this is from the
VSGNE database. And, I know on a VQI, we do put down
whether there has been any preoperative evaluation. Was that
not available in this data set that you aren’t aware of that?
Dr Simons. No, we did have access to that variable. And,
we did include in some of our analyses whether or not a preop-
erative stress test was performed. And, it was not performed for
the majority of patients. I think it was positive only in an
extremely small percentage, as you would expect to ﬁnd.
Regardless, it ultimately didn’t end up being signiﬁcant on
univariate screening, and that’s why it didn’t make it into the
ﬁnal analysis.
